Liraglutide (Saxenda) and semaglutide (Wegovy), both GLP-1 receptor agonists, can cause modest increases in resting heart rate (typically a mean rise of approximately 24 beats per minute, though some individuals may experience larger increases)
Clinical trials show that these effects begin within days, though measurable weight loss on the scale typically lags appetite suppression by 1 to 3 weeks
On the research side, Eli Lilly's orforglipron, an oral non-peptide small-molecule GLP-1 receptor agonist, has reported positive Phase 3 results but is not FDA-approved as of April 2026, so it is not yet a purchasable pill
Related products AS09 602 | Clonality: Polyclonal | Host: Goat | Reactivity: Rabbit IgG (H&L) AS09 607 | Clonality: Polyclonal Host: Goat Reactivity: Rabbit IgG (H&L)
PMID 38823477
En entrenamientos de resistencia o sesiones de cardio , este timing suele ser el ms recomendado